	US 12,378,524 B2
	Methods of mediating macrophage phenotypes
Jennifer E. Woodell-May, Warsaw, IN (US); Joel C. Higgins, Claypool, IN (US); and William King, Warsaw, IN (US)
Assigned to Biomet Manufacturing, LLC, Warsaw, IN (US)
Filed by Biomet Manufacturing, LLC, Warsaw, IN (US)
Filed on Jan. 28, 2021, as Appl. No. 17/161,302.
Application 17/161,302 is a division of application No. 15/797,796, filed on Oct. 30, 2017, granted, now 10,946,043.
Application 15/797,796 is a division of application No. 14/554,381, filed on Nov. 26, 2014, granted, now 9,833,474.
Claims priority of provisional application 61/928,284, filed on Jan. 16, 2014.
Claims priority of provisional application 61/909,249, filed on Nov. 26, 2013.
Prior Publication US 2021/0236544 A1, Aug. 5, 2021
Int. Cl. C12N 5/0786 (2010.01); A61K 35/16 (2015.01); A61K 40/17 (2025.01); A61K 40/22 (2025.01); A61K 40/24 (2025.01); A61K 40/41 (2025.01); C12N 5/0775 (2010.01)

CPC C12N 5/0645 (2013.01) [A61K 40/17 (2025.01); A61K 40/22 (2025.01); A61K 40/24 (2025.01); A61K 40/416 (2025.01); C12N 5/0667 (2013.01); A61K 35/16 (2013.01); C12N 2501/20 (2013.01); C12N 2502/1382 (2013.01)]

7 Claims

1. A method for treating inflammation in a subject in need thereof, comprising:

(a) generating a protein solution comprising about 5 μg/ml or greater interleukin-4 (IL-4), about 2 μg/ml or greaterinterleukin-10, and transforming growth factor-beta;

(b) contacting the protein solution with a concentrated bone marrow aspirate (cBMA), wherein a ratio of the protein solution to cBMA is in a range of from about 1:10 to about 10:1;

(c) contacting an isolated source of macrophages with the protein solution to induce the macrophages to polarize into an M2 phenotype; and

(d) administering the M2 macrophages to the subject at the site of inflammation.